Furthest along
3 approved
3 in Phase 3
Drugs
23
in active trials · 31 in all
Trials
82 active
164 since 2021
Drugs23
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
PD-1/CTLA-4 bispecific antibody |
Approved in China | 30 Nov 2026soonPhase 2 trial completes | |||
| How it works | A cancer drug that hits three targets | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma and 23 more | ||||
| Open drug page | |||||
PD-1/VEGF bispecific antibody |
Summit Therapeutics |
Approved in China | 1 Dec 2026soonPhase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 1 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Advanced Solid Tumors and 95 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | Dec 2026Phase 1/2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Nasopharyngeal Carcinoma, Non-small Cell Lung Cancer Stage IIIB/IV and 3 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | Nov 2026soonPhase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, Gastric and Gastroesophageal Junction Adenocarcinoma | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | 30 Dec 2026Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Myelodysplastic Syndrome, Acute Myeloid Leukemia and 10 more | ||||
| Open drug page | |||||
AK120not checked |
— |
Phase 3 | 10 Jul 2027Phase 3 trial completes | ||
| Next date | 10 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis | ||||
| Open drug page | |||||
— |
Phase 2 | 27 Dec 2026Phase 2 trial completes | |||
| Next date | 27 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Asthma, Seasonal Allergic Rhinitis and 4 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor, Adult, Colorectal Cancer | ||||
| Open drug page | |||||
— |
Phase 1/2 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Classic Hodgkin Lymphoma, Non-small Cell Lung Cancer Stage IIIB/IV and 3 more | ||||
| Open drug page | |||||
— |
Phase 2 | 28 Feb 2027Phase 1/2 trial completes | |||
| Next date | 28 Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Malignant Solid Tumor, Colorectal Cancer With Hepatic Metastases and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | May 2027Phase 1/2 trial completes | |||
| Next date | May 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Biliary Tract Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Aug 2027Phase 2 trial completes | |||
| Next date | 30 Aug 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumors, Advanced Breast Cancer and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 6 Jun 2028Phase 1/2 trial completes | |||
| Next date | 6 Jun 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Cancer, Breast Cancer and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Hepatocellular Carcinoma | ||||
| Open drug page | |||||
— |
Phase 1 | May 2027Phase 1 trial completes | |||
| Next date | May 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Malignant Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | Jun 2027Phase 1 trial completes | |||
| Next date | Jun 2027 · Phase 1 trial completes | ||||
| Also tested for | Alzheimer' s Disease | ||||
| Open drug page | |||||
— |
Phase 1 | 23 Feb 2028Phase 1 trial completes | |||
| Next date | 23 Feb 2028 · Phase 1 trial completes | ||||
| Also tested for | Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma | ||||
| Open drug page | |||||
AK158D1not checked |
— |
Phase 1 | 30 Apr 2028Phase 1 trial completes | ||
| Next date | 30 Apr 2028 · Phase 1 trial completes | ||||
| Also tested for | Solid Malignant Tumor | ||||
| Open drug page | |||||
— |
Phase 1 | 21 Feb 2029Phase 1 trial completes | |||
| Next date | 21 Feb 2029 · Phase 1 trial completes | ||||
| Also tested for | Advanced Malignant Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | 30 Mar 2029Phase 1 trial completes | |||
| Next date | 30 Mar 2029 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 8 other drugs
- SEC filings
- None: it does not file with the US SEC
- Registry names
- 2 names in ClinicalTrials.gov Akeso
Akesobio Australia Pty Ltd - Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev